ESPEYB15 9 Oncology and chronic disease Biologic agents in chronic inflammatory diseases: lights and shadows (3 abstracts)
9.12 Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn’s Disease
Walters TD , Faubion WA , Griffiths AM , Baldassano RN , Escher J , Ruemmele FM , Hyams JS , Lazar A , Eichner S , Huang B , Li Y & Thakkar RB
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada
To read the full abstract: Inflamm Bowel Dis. 2017;23:967-975
Approximately one-third of children and adolescents with Crohn disease (CD) suffer from growth failure and delayed puberty, leading in some to psychological and social dysfunction, especially in boys. Pubertal delay in CD may also impact the normal growth spurt and lead to short adult height. The aim of therapy in children with CD is to achieve remission, improve quality of life, and enable patients to attain full adult height potential. The IMAgINE 1 study (ClinicalTrials.gov identifier, NCT00409682) was a 52-week, phase 3, multicenter, randomized, double-blind trial that assessed the efficacy and safety of 2 induction doses and 2 maintenance dose regimens of adalimumab (ADA) in 6 to 17-year-old patients with moderately to severely active CD. This paper reports the effect of ADA treatment on linear growth in a group of 100 children participating in this study. Restoration of normal growth was associated with clinical remission and was particularly relevant in patients showing early and good response to ADA therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more